AGMB (AgomAb Therapeutics NV) Retained Earnings: $-212.78 Mil (As of Dec. 2025)


AGMB AgomAb Therapeutics NV AGMB
14 GF Score
Price $13.08
! 1 Warning Sign
View Full Analysis

What is AgomAb Therapeutics NV Retained Earnings?

AgomAb Therapeutics NV AGMB +0.85% 14 Retained Earnings is $-212.78 Mil as of Dec. 2025. GuruFocus rates AGMB with a GF Score™ of 14/100. The stock has 1 warning sign investors should review.

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. AgomAb Therapeutics NV's retained earnings for the quarter that ended in Dec. 2025 was $-212.78 Mil.

AgomAb Therapeutics NV's quarterly retained earnings declined from Dec. 2024 ($-124.80 Mil) to Sep. 2025 ($-192.80 Mil) and declined from Sep. 2025 ($-192.80 Mil) to Dec. 2025 ($-212.78 Mil).

AgomAb Therapeutics NV's annual retained earnings declined from Dec. 2023 ($-79.42 Mil) to Dec. 2024 ($-124.80 Mil) and declined from Dec. 2024 ($-124.80 Mil) to Dec. 2025 ($-212.78 Mil).

AgomAb Therapeutics NV  (NAS:AGMB) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.

AgomAb Therapeutics NV Retained Earnings Historical Data

* Premium members only.

The historical data trend for AgomAb Therapeutics NV's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

AgomAb Therapeutics NV Retained Earnings Chart

AgomAb Therapeutics NV Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Retained Earnings
-50.64 -65.09 -79.42 -124.80 -212.78

AgomAb Therapeutics NV Quarterly Data
Dec21 Dec22 Dec23 Dec24 Sep25 Dec25
Retained Earnings Get a 7-Day Free Trial -65.09 -79.42 -124.80 -192.80 -212.78
AGMB
14GF Score
AgomAb Therapeutics NV AGMB
Retained Earnings is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

AgomAb Therapeutics NV Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.

Frequently Asked Questions Learn more about Retained Earnings →
What does a Retained Earnings of $-212.78 Mil mean?
AgomAb Therapeutics NV (AGMB) has a Retained Earnings of $-212.78 Mil as of Dec. 2025. Retained earnings is the amount of net income not issued to shareholders. View historical data on AgomAb Therapeutics NV and its competitors.
Is AgomAb Therapeutics NV's Retained Earnings too high?
AgomAb Therapeutics NV's current Retained Earnings is $-212.78 Mil. Overall, AgomAb Therapeutics NV has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does AgomAb Therapeutics NV's Retained Earnings compare to DNA and ACRS?
AgomAb Therapeutics NV's Retained Earnings of $-212.78 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Retained Earnings for a Biotechnology company?
A good Retained Earnings depends on the Biotechnology industry context. However, Retained Earnings should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Retained Earnings mean?
A high Retained Earnings can signal that a stock is expensive relative to its fundamentals. Retained earnings is the amount of net income not issued to shareholders. View historical data on AgomAb Therapeutics NV and its competitors. AgomAb Therapeutics NV's current Retained Earnings is $-212.78 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AgomAb Therapeutics NV stock overvalued right now?
AgomAb Therapeutics NV (AGMB) has a current Retained Earnings of $-212.78 Mil. The current Retained Earnings is $-212.78 Mil. AgomAb Therapeutics NV's overall GF Score™ is 14/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Retained Earnings calculated?
Retained Earnings is calculated from a company's financial statements. For AgomAb Therapeutics NV (AGMB), the current Retained Earnings is $-212.78 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

AgomAb Therapeutics NV Business Description

Address 1/6 Posthoflei, Antwerp, BEL, 2600
AgomAb Therapeutics NV is a clinical-stage biopharmaceutical company focused on developing novel disease-modifying therapies for immunology and inflammatory diseases, with an initial focus on chronic fibrotic indications with high unmet medical need. Its product candidates are designed to target established pathways and utilize validated modalities, with a focus on addressing limitations associated with prior treatment approaches. The company's pipeline includes small molecule and antibody product candidates aimed at targets associated with fibrotic diseases. Key candidates include Ontunisertib (AGMB-129) and AGMB-447.
14GF Score

Get the complete analysis for AGMB

Retained Earnings is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$13.08
Price